LAEKNA, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.5 HKD | +1.90% |
|
+13.46% | -62.31% |
| May. 10 | Laekna Gets Investigational New Drug Approval from Chinese Regulator for Obesity Drug | MT |
| May. 10 | Lekna, Inc. Obtains IND Approval from the CDE for LAE102 | CI |
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 |
|---|---|---|
| Net sales 1 | 0.111 | 0.28 |
| EBITDA 1 | -222.4 | -391 |
| EBIT 1 | -225 | -393.3 |
| Operating Margin | -202,729.73% | -140,470% |
| Earnings before Tax (EBT) 1 | -749 | -781.6 |
| Net income 1 | -749 | -781.6 |
| Net margin | -674,742.34% | -279,140.71% |
| EPS 2 | -10.54 | -10.19 |
| Free Cash Flow | - | -180 |
| FCF margin | - | -64,280.94% |
| FCF Conversion (EBITDA) | - | - |
| FCF Conversion (Net income) | - | - |
| Dividend per Share | - | - |
| Announcement Date | 6/15/23 | 6/15/23 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 |
|---|---|---|
| Net Debt 1 | - | - |
| Net Cash position 1 | 269 | 295 |
| Leverage (Debt/EBITDA) | - | - |
| Free Cash Flow | - | -180 |
| ROE (net income / shareholders' equity) | - | 51.8% |
| ROA (Net income/ Total Assets) | - | -52.4% |
| Assets 1 | - | 1,492 |
| Book Value Per Share 2 | -15.60 | -24.00 |
| Cash Flow per Share 2 | 4.170 | 4.070 |
| Capex 1 | 7.32 | 2.98 |
| Capex / Sales | 6,591.89% | 1,065.36% |
| Announcement Date | 6/15/23 | 6/15/23 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -62.31% | 368M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- 2105 Stock
- Financials Laekna, Inc.